Danusertib

Manufactured by Selleck Chemicals

Sourced in United States

Danusertib is a small-molecule inhibitor that targets multiple kinases, including Aurora kinases, Bcr-Abl, and FGFR. It is used as a research tool in studies investigating cell signaling pathways and cellular processes.

Automatically generated - may contain errors

Lab products found in correlation

Fetal bovine serum (fbs), by Thermo Fisher Scientific (2 mentions) Azd1152, by Selleck Chemicals (2 mentions) Mln8237, by Selleck Chemicals (2 mentions) Pvdf transfer membrane, by Thermo Fisher Scientific (1 mentions) 4 6 diamidino 2 phenylindole (dapi), by Merck Group (1 mentions) Anti caspase 9, by Cell Signaling Technology (1 mentions) Imatinib, by Selleck Chemicals (1 mentions) Anti β actin antibody, by Santa Cruz Biotechnology (1 mentions) Volasertib, by Selleck Chemicals (1 mentions) Azd1775, by Selleck Chemicals (1 mentions) Fitc conjugated anti mouse igg, by Merck Group (1 mentions) Anti chk1, by Cell Signaling Technology (1 mentions) Anti phospho cdc25c, by Cell Signaling Technology (1 mentions) Anti aurora kinase a, by Cell Signaling Technology (1 mentions) Anti caspase 3, by Cell Signaling Technology (1 mentions) Iodoacetamide iaa, by Merck Group (1 mentions) Sequencing grade trypsin, by Promega (1 mentions) Dithiothreitol (dtt), by Merck Group (1 mentions) Ibrutinib, by Selleck Chemicals (1 mentions) Lc ms grade acetonitrile acn, by Avantor (1 mentions)

6 protocols using danusertib

Cell Proliferation Evaluation of CCSER1

Check if the same lab product or an alternative is used in the 5 most similar protocols

HeLa sgRNA and RPE hTERT, previously infected with pLenti DDK mock and pLenti DDK r-CCSER1 (as described before) were plated in 60-mm dishes in triplicate (20,000 cells/well) with a complete medium. The cells were detached and counted in triplicate at the indicated time points with a Burker cell chamber after Trypan Blue staining to exclude apoptotic/necrotic cells. Where indicated, a two-way ANOVA with a multiple-comparison test was applied. DLD1 cells, previously infected with pCCLsin.PPT.pGK.GFP.Wpre.3′ LTR-U6.sgRNA and pCCLsin.PPT.pGK.BFP.Wpre.3′ LTR-U6.sgRNA and then “crisped” with pLenti Puro CAS9 were plated in a 96-well plate in triplicate (2,000 cells/well) with complete medium. CellTiter-Glo Luminescent Cell Viability Assay is performed at the indicate time points, according to the manufacturer instructions. For drug evaluation, Danusertib (Danusertib [PHA-739358] S1107; Selleck Chemicals) was added to medium 24 h after plating.

Santoliquido B.M., Frenquelli M., Contadini C., Bestetti S., Gaviraghi M., Barbieri E., De Antoni A., Albarello L., Amabile A., Gardini A., Lombardo A., Doglioni C., Provero P., Soddu S., Cittaro D, & Tonon G. (2021). Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene. Life Science Alliance, 4(8), e202101019.

+ Open protocol

+ Expand

Molecular Mechanisms of Cell Cycle Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Imatinib, danusertib, volasertib and AZD1775 were purchased from Selleck Chemicals. For Western blotting, 10% acrylamide gels, running buffer (MOPS), transfer buffer and polyvinylidene difluoride (PVDF) transfer membrane were bought from Thermo Scientific. For immunofluorescence (IF), the FITC-conjugated anti-mouse IgG, the anti-rabbit conjugated with Alexa Fluor 568 antibodies and DAPI (6-diamidino-2-phenylindole) were purchased from Sigma-Aldrich.
The anti-cleaved-caspase 3 (Asp175), anti-cleaved-caspase 9 (Asp353), anti-BAX, anti-CHK1, anti-phospho-CHK1 (S317), anti-CHK2, anti-phospho-CHK2 (T68), anti-cyclin B1, anti-phospho-cyclin B1 (S133), anti CDC25C, anti-phospho-CDC25C (S198), anti-WEE1, anti-phospho-WEE1 (S642), anti-CDK1, anti-phospho-CDK1 (Y15), anti-phospho-H2AX (S139), anti-RAD51, anti- β-tubulin Alexa Fluor 555 Conjugate, anti-Aurora kinase A, anti-phospho-Aurora kinase A (T288), anti-PLK1, anti-phospho-PLK1 (T210), anti-PARP, anti-caspase-3 and anti-caspase-9 antibodies were purchased from Cell Signaling Technology. The anti-β-actin antibody used as loading control was purchased from Santa Cruz Biotechnology.

Mancini M., De Santis S., Monaldi C., Castagnetti F., Lonetti A., Bruno S., Dan E., Sinigaglia B., Rosti G., Cavo M., Gugliotta G, & Soverini S. (2022). Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. Frontiers in Oncology, 12, 901132.

+ Open protocol

+ Expand

Mass Spectrometry Analysis of Screened Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

D-luciferin was purchased from Gold Biotechnologies (St. Louis, MO). Screened compounds are described below. Repurchased hits, including Momelotinib, TG101209, Fedratinib, Pacritinib, Danusertib, Saracatinib, Ibrutinib, and Bosutinib were obtained from Selleck (Houston, TX). For mass spectrometric experiments, LC–MS grade acetonitrile (ACN) and water were from J.T. Baker (Philipsburg, NJ). Formic acid was obtained from Pierce (Rockford, IL) and iodoacetamide (IAA) and dithiothreitol (DTT) were purchased from Sigma-Aldrich (St. Louis, MO). Sequencing grade trypsin was supplied by Promega (Madison, WI).

Wadsworth P.A., Singh A.K., Nguyen N., Dvorak N.M., Tapia C.M., Russell W.K., Stephan C, & Laezza F. (2020). JAK2 regulates Nav1.6 channel function via FGF14Y158 phosphorylation. Biochimica et biophysica acta. Molecular cell research, 1867(10), 118786.

+ Open protocol

+ Expand

SCLC Cell Line Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

All SCLC cell lines were provided by Dr. John V. Heymach (MD Anderson Cancer Center, Houston, TX) and Dr. Gerold Bepler (Barbara Ann Karmanos Cancer Institute, Detroit, MI). All cell lines, maintained in a central bank at Moffitt, were authenticated by STR analysis (ACTG Inc, Wheeling, IL), and all are routinely tested and shown to be negative for mycoplasma (PlasmoTest, InvivoGen, San Diego, CA). All cell lines were grown in RPMI 1640 media with 10% fetal bovine serum (GIBCO, Grand Island, NY) and maintained at 37°C in a humidified incubator with 5% CO₂ atmosphere. The Roche Kinase Inhibitor Set was a gift of Hoffman-La Roche (San Diego, CA). SNS-314, danusertib, AT9283, MLN-8237, ENMD-2076, TAK-901, AZD1152, and VX-680 were purchased from Selleckchem (Houston, TX). The TANK-binding kinase 1 (TBK1) inhibitor Compound II and BX-795 were provided by Dr. Michael White (University of Texas Southwestern Medical Center, Dallas, TX).

Li J., Fang B., Kinose F., Bai Y., Kim J.Y., Chen A., Rix U., Koomen J.M, & Haura E.B. (2016). Target identification in small cell lung cancer via integrated phenotypic screening and activity-based protein profiling. Molecular cancer therapeutics, 15(2), 334-342.

+ Open protocol

+ Expand

Screening of Protein Kinase Inhibitors for TNBC

Check if the same lab product or an alternative is used in the 5 most similar protocols

The fifty-five protein kinase inhibitors (PKIs) were purchased from following sources: BML-275, FR 180204, IKK16, GW 843682X, NSC 109555, NU7441, PD407824, PF 573228, SB 218078, TCS PIM-1-1, TCS PIM-1-4a, and TPCA-1 from Tocris Biosciences (Bristol, UK); indirubin-3′-monoxime and Ro-31-8220 from Calbiochem (San Diego, CA, USA); A-769662, bosutinib, chelerythrine, CP690550, fasudil, gefitinib, imatinib, nilotinib, PKC412, roscovitine, SNS-314, and tozasertib from LC Laboratories (Woburn, MA, USA); AT7867, AT9283, AZD1152, AZD1480, BI 2536, BIX 02189, CHIR-99021, CI-1040, CYC116, danusertib, enzastaurin, GDC-0879, INCB018424, JNJ-7706621, KU-55933, LY2228820, MLN8237, PD-0325901, PF-4708671, PLX-4032, PLX-4720, SB216763, SNS-032, SP600125, VX-702, Y-27632, and ZM447439 from Selleck Chemicals (Houston, TX, USA); U0126 from Promega (Madison, WI, USA); TBCA from Millipore (Burlington, MA, USA).
All TNBC cells in this study were obtained from the American Type Culture Collection (Manassas, VA, USA). The cultured cells were monitor by trypan blue cell counting as described previously [58 (link)].

Yi Y.W., You K.S., Han S., Ha I.J., Park J.S., Lee S.G, & Seong Y.S. (2022). Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells. Cancers, 14(21), 5215.

+ Open protocol

+ Expand

Expansion and Drug Treatment of CD34+ Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

CD34⁺ cells were seeded into individual wells of a 96 well tissue-culture treated flat bottom polystyrene plate (1 × 10⁴ cells/well in 200 µL) in SFEM II medium (STEMCELL Technologies; 09655) supplemented with 10% FBS (Gibco; 10082-147), 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco; 15140-122), 12.5 μg/ml aprotinin (Sigma–Aldrich; A3428), 20 ng/ml EPO (PeproTech; 100-64), 1 ng/ml G-CSF (PeproTech; 300-23), 100 ng/ml Flt3-L (PeproTech; 300-19), 100 ng/ml TPO (PeproTech; 300-18), 50 ng/ml SCF (PeproTech; 300-07) and select EGM-2 BulletKit (Lonza; CC-4176) components (hFGF-B, VEGF, R3-IGF-1, hEGF, ascorbic acid and heparin), according to the manufacturer’s instructions. Medium was changed on days 2 and 4 and every day afterwards. Cells were split 2x on both day 7 and day 10 of culture.
AZD2811 was obtained from AstraZeneca while Danusertib and Tozasertib were purchased from Selleckchem. Drugs were reconstituted in DMSO, stored frozen at −20 C, and then diluted into the above cell culture medium for use. To start drug treatment on day 10, cells were harvested into V-bottom polypropylene plates and centrifuged at room temperature for 5 min at 300xg. The supernatant was then aspirated and the cells were resuspended in medium containing drug or DMSO and transferred back to 96 well tissue-culture treated flat bottom polystyrene plates.

Chou D.B., Furlong B.A., Posey R.R., Kyprianou C., O’Sullivan L.R., David R., Randle S.J., Polanska U.M., Travers J., Urosevic J., Hutchinson J.N., Che J., Howley A.M., Hasserjian R.P., Prantil-Baun R, & Ingber D.E. (2022). Differential ABC transporter expression during hematopoiesis contributes to neutrophil-biased toxicity of Aurora kinase inhibitors. Nature Communications, 13, 6021.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!